Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about deals, orders, contracts, projects, customers, sites, or programs. We need to see if management conveys that the unit size of its repeatable business is escalating. Looking at the transcript, management discusses acquisitions, growth, and strategy. They mention the Lima acquisition, which is a large deal, but that's an acquisition, not a repeatable business engagement. They talk about organic growth, share gains, and innovation. They mention new products like EMPOWR Revision Knee, ARVIS 2.0, Evolve34 Lapidus Correction System. They talk about P&R growth, MotionMD clinic conversions. But do they say that the size of individual deals, orders, contracts, or projects is increasing? They mention "clinic conversions" which might be larger engagements, but they don't explicitly compare sizes over time. The question is about "successive engagements of the same kind" coming in at progressively larger size. For example, if they sell implants, are they selling larger volumes per hospital? Or if they have distribution agreements, are they signing bigger ones? The transcript doesn't seem to have that. They talk about growth in organic sales, but that could be from more units or price. They mention "share gain" and "above-market growth" but not about individual deal size escalation. They also discuss the Lima acquisition as a step change, but that's a one-time acquisition, not a repeatable business engagement. They mention "we have a strong pipeline of innovation" and "we are confident in our ability to continue to drive this compounding growth" but that's about growth overall, not about unit size escalation. The question specifically asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" I don't see any such statement. They talk about "MotionMD clinic conversions" which might be larger, but they don't compare to past. They talk about "new products" but that's not about size of engagements. They also mention "we have a lot of experience and track record doing acquisitions well" but that's about acquisitions, not repeatable business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.